Single-Cell Analysis: Visualizing Pharmaceutical and Metabolite Uptake in Cells with Label-Free 3D Mass Spectrometry Imaging by Passarelli, Melissa K. et al.
Single-cell Analysis: Visualizing Pharmaceutical and
Metabolite Uptake in Cells with Label-free 3D Mass
Spectrometry Imaging
Melissa K. Passarelli,∗,† Carla F. Newman,∗,‡ Peter S. Marshall,‡ Andrew West,‡
Ian S. Gilmore,†,¶ Josephine Bunch,†,¶ Morgan R. Alexander,¶ and Colin T.
Dollery‡
National Centre of Excellence in Mass Spectrometry Imaging (NiCE-MSI), National Physical
Laboratory (NPL), Teddington, Middlesex, TW11 0LW, U.K., GlaxoSmithKline, Stevenage, UK.,
and Univerity of Nottingham, School of Pharmacy University Park, Nottingham, NG7 2RD, U.K.
E-mail: melissa.passarelli@npl.co.uk; carla.f.newman@gsk.com
Abstract
Detecting metabolites and parent compound within a cell type is now a priority for phar-
maceutical development. In this context, three-dimensional secondary ion mass spectrome-
try (SIMS) imaging was used to investigate the cellular uptake of the antiarrhythmic agent
amiodarone, a phospholipidosis-inducing pharmaceutical compound. The high lateral resolu-
tion and 3D imaging capabilities of SIMS combined with the multiplex capabilities of ToF
mass spectrometric detection allows for the visualization of pharmaceutical compound and
metabolites in single cells. The intact, unlabeled drug compound was successfully detected at
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therapeutic dosages in macrophages (cell line: NR8383). Chemical information from endoge-
nous biomolecules was used to correlate drug distributions with morphological features. From
this spatial analysis, amiodarone was detected throughout the cell with the majority of the
compound found in the membrane and subsurface regions and absent in the nuclear regions.
Similar results were obtained when the macrophages were doped with amiodarone metabolite,
desethylamiodarone. The FWHM lateral resolution measured across an intracellular interface
in a high lateral resolution ion images was approximately 550 nm. Overall, this approach pro-
vides the basis for studying cellular uptake of pharmaceutical compounds and their metabolites
on the single cell level.
In pharmacology, it is often assumed that the drug concentration at the effector site is equivalent
to the serum concentration.1 However, this is often not the case, as factors such as cellular uptake,
sequestering and accumulation can affect the amount of drug that reaches the target site and skews
the dose-response dynamic. In a recent review,2 it is highlighted "that many drug targets are
intracellular...[and therefore] to predict the pharmacological effect accurately, there must be data
concerning the concentration at the target" and that "knowledge of the drug concentration at its
site of action within cells is becoming increasingly important in pharmacology and therapeutics."
Consequently, the ability to analyze drug compounds in the complex cellular environments is a
priority for modern pharmaceutical research. Indeed, evaluating drug uptake on the single cell
level would provide new opportunities in drug development by evaluating more precisely the dose-
response behavior of individual cells.
Mass spectrometry imaging (MSI) techniques are well-suited for analyzing drug distributions
in biological materials. The method has the advantage of being label-free and capable of multi-
plexed analyzes when coupled to a ToF mass analyzer. The parallel detection of the drug com-
pound and the local endogenous chemistry permits the correlation of drug distributions with re-
spect to morphological features. MALDI and DESI are currently the main MSI methodologies
used by pharmaceutical companies, these methods have been successfully employed to investigate
drug distributions in tissues.3–6 Unfortunately these methods do not have the lateral resolution to
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achieve sub-micrometer imaging, however, it is worth noting that recent technological advances
in the field of MALDI has improved the lateral resolution to a few micrometers, thus allowing the
visualization of large cells and organelles.7–9
In this context, 3D ToF-SIMS imaging is a potentially powerful analytical platform for the
pharmaceutical industry. SIMS has been successfully applied to investigating drug distribution in
medical devices10 and various drug delivery systems.11,12 The sub-micron lateral resolution and
nanometer depth resolution of SIMS opens the possibility for three-dimensional molecular imag-
ing of pharmaceuticals at the single cell level.13–17 Although, sensitivity and matrix effects have
limited the role of SIMS in pharmacology, technological advancements, particularly the advent of
cluster ion sources, have improved the technique’s sensitivity.18,19 The advantage of cluster sources
is two-fold; as an analysis beam cluster sources improve molecular ion yields and as a sputtering
beam, they reduce damage accumulation allowing the molecular ion sensitivity to be maintained
throughout the sample. With these advances, as demonstrated here, the use of SIMS in the analysis
of pharmaceutical compounds and their metabolites in single cell is now achievable.
In this report, 3D ToF-SIMS imaging was used to successfully detect the anti arrhythmia drug
compound amiodarone and its metabolite, desethylamiodarone, in single macrophages. The intact
molecular ion of the target drug compound amiodarone, m/z 646.0, was detected throughout the
cell. The majority of the compound signal was observed in the surface and subsurface regions
of the cell. Although the molecular ion signal intensity dissipates with depth, the signal of the
molecular ion is still observed above a signal-to-noise (S/N) level of 3 throughout the analysis.
Overall, this study demonstrates the potential of ToF-SIMS as a bio-analytical method for the
analysis of cellular uptake of drugs and metabolite at the single cell level.
Experimental Methods
Cell culture. NR8383 cells, an immortalized cell line derived from a lung macrophage (Sprague-
Dawley rat), were grown on Nunc Lab-Tek II Chamber slides (Thermo Scientific, USA) with
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Ham’s F-12 Nutrient Mixture medium containing GlutaMax and Phenol Red (Gibco, USA) and 15
% dialyzed, heat-inactivated fetal bovine serum (Gibco, USA). 5 mg/mL stock solutions of amio-
darone hydrocholoride (Sigma-Aldrich, CAS 19774-82-4, purity≥ 98 %) andN-desethylamiodarone
hydrochloride solution (Sigma-Aldrich, CAS 96027-74-6) were prepared in 50:50 water/ MeOH.
The stock solutions were added to the growth medium for a final medium concentration of 1.56
µg/mL. The cells were incubated (5 % CO2 and 37 ◦C) in the drug or metabolite doped medium
solution for 72 hrs. Control cells were incubated alongside the doped cells.
Freeze-drying procedure. The medium was removed and the cells were washed three times
with 150 mM ammonium formate solution (pH-balanced, Sigma-Aldrich, USA).20 Excess liquid
was removed and the cells were frozen using a CoolSink XT 96F plate (BioCision, USA) at -80
◦C. The frozen cells were dried under vacuum in a miVac with SpeedTrap (Genevac, USA) for
approximately 1 hour. The samples were stored at -80 ◦C. Before ToF-SIMS analysis the samples
were warmed to room temperature in a vacuum chamber.
Instrumentation. ToF-SIMS analyses were performed on a TOF-SIMS IV mass spectrometer
(ION-TOF GmbH, Münster, Germany). The dual beam experiment used a 25 keV Bi+3 primary
ion beam for imaging and a 20 keV Ar+2000 beam for sputtering. The bismuth ion source was
operated using two imaging mode; the high current, high mass resolution mode and the high lateral
resolution mode.
High mass resolution ion images were collected over a surface area of 125 µm x 125 µm using
a pulsed analysis beam (pulse width = 23 ns, mass resolution (m/∆m) at m/z 646 ∼3400). At 256
x 256 pixels per image, the pixel width was 0.5 µm. Each image was obtained with a final ion
dose of 2.2 x 1012 primary ions/cm2. The dose was kept below the static limit of the 1013 primary
ions/cm2 to minimize surface damage. After recording each image, the sample was eroded with
a sputter beam with an Ar+2000 ion dose of 3.7 x 10
13 ions/cm2 over an area 250 µm x 250 µm.
The total acquisition time for each 3D image was approximately 2 hrs. Data was collected in the
positive secondary ion mode.
High lateral resolution ion images were collected over a surface area of 50 µm x 50 µm using
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a pulsed analysis beam (pulse width = 100 ns, mass resolution (m/∆m) at m/z 127 ∼ 335). At 256
x 256 pixels per image, the pixel width was 0.2 µm. Each image was obtained with a final ion dose
of 6.5 x 1011 primary ions/cm2. After recording each image, the sample was eroded with a sputter
beam with an Ar+2000 ion dose of 3.9 x 10
13 ions/cm2.
All image analyzes were performed using ION-TOF SurfaceLab (Version 6.3, ION-TOF, Mün-
ster, Germany) and MATLAB 2014a. Individual cells were outlined with a polyline tool using the
total ion count image and pixels above the threshold (25% of the total ion counts) were selected
as regions of interest (ROI). Chemical structures were drawn in ChemDraw 14.0. The high lateral
resolution imaging experiments were collected in the negative secondary ion mode. Image lat-
eral resolution measurement were obtained by plotting the ion intensities for the various analytes
across an intracellular features. The linescans were fitted with a error function and the FWHM
lateral resolution was measured.21,22
Results and Discussion
Amiodarone [KEGG drug: D02910] is an effective Vaughan-Williams class III antiarrhythmic
medication (potassium channel blocker) known to delay repolarization in the smooth muscle cell
in the heart, resulting in heartbeats with prolonged action potential durations and refractory pe-
riods.23 Unfortunately, the therapeutic value of amiodarone is diminished by adverse and poten-
tially dangerous side effects.24 In clinical studies, the concentration of amiodarone in serum was
correlated to therapeutic and toxic effects in patents.25 For patients with amiodarone serum con-
centrations below 1 µg/mL, the effectiveness of the drug as an anti-arrhythmia agent was reduced.
While, patients with amiodarone serum concentrations above 2.5 µg/mL often experience adverse
reactions. Long-term usages of amiodarone leads to drug induced phospholipidosis, a lysosomal
storage disorder characterized by the prevalence of "foamy" or lipid-laden macrophages.
Although the link between foamy macrophages and drug-induced toxicity is unclear, the im-
pairment of cellular functions and the accumulation for lipids in macrophages has been the subject
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of numerous investigated.26–29 Amiodarone is a cationic amphiphilic drug whose hydrophobic
domain allows it to cross the lipid membrane, including that of the lysosome. Inside the acidic
environment of the lysosome, amiodarone is hydrolyzed.28 It is speculated that the drug accu-
mulates in the lysosome, as it is unable to re-cross the membrane in the hydrolyzed state, and
inhibits the degradation of phospholipase A, a protein responsible for lipid catabolism.29 As a re-
sult, phospholipids and drug accumulate in the lysosomes and impairs cellular functions. Although
the inhibition of late stage endosomal processes has been shown to suppresses virus activation30
(e.g. SARS), a attribute that may broaden the therapeutic application of amiodarone, without a
clear understanding of the drug’s role in organ-based toxicity, the therapeutic value of amiodarone
is limited.
Lipid accumulations in foamy macrophages are visible with histological staining and light
microscopy and are also detected as lamellar inclusion bodies with electron microscopy. It is
important to note, that these detection methods do not provide information on the presence of the
drug, but only detect the morphological changes caused by the drug. Therefore, a method, such
as SIMS, with the ability to directly detect the drug compound inside individual cell may provide
clues as to its potential toxicity.
In this investigation, the intact protonated molecule, [M+H]+, of the drug compound amio-
darone, C25H29I2NO3, was detected at m/z 646.0 in the drug-doped lyophilized macrophages
(see Figure 1A). The peak and isotope pattern was in agreement with the reference spectrum
and theoretical isotope pattern for amiodarone (see Supporting Information, Figure-S1). A peak
at m/z 520.1 was also detected and identified as protonated amiodarone with a missing iodine,
[C25H30INO3+H]+. The peak at m/z 520.1 was also present in the reference spectrum.
The total ion contribution for the amiodarone related peaks at m/z 646.0 and m/z 520.1, dis-
played in Figure 1B, shows that amiodarone is localized within the cells. The distribution of
amiodarone across the cell appears to be relatively uniform, except in the region indicated with the
white arrow. The absence of amiodarone signal in this region is made clear when we examined
the endogenous species in this region. This region is occupied by a number of known nuclear
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markers, including the molecular ion of adenine, a purine nucleobase, at m/z 136.1 and a frag-
ment of ribose, C5H5O+ at m/z 81,31,32 the sugar functional group that makes up the backbone
of RNA and DNA. Additional oxygenated hydrocarbon species, including C5H6O2+ at m/z 98.0,
C4H4O+ at m/z 68.0 and C3H4O+ at m/z 56.0 also co-localized to the nucleus. The cell nucleus
was unequivocally identified using the chemical cues from the mass spectrum and as expected, the
drug compound is not observed in this region of the cell. The phosphocholine fragment (m/z 184),
ribose fragment (m/z 81) and amiodarone (m/z 646) ion intensities across the large cell, defined as
ROI 1, is shown in Figure 1E. The intracellular interface between the ribose and drug signal was
fitted with a error function (erf). Assuming that the lateral resolution is limited by the diameter of
the Gaussian -shaped ion beam, the full width half maximum (FWHM) lateral resolution, which is
equivalent to 2.3548 times the standard deviation, σ , was calculated to be 3.4 µm.
In Figure 1C, we also mapped endogenous species that co-localize with the drug compound, in-
cluding phosphocholine fragment species C5H12N+ at m/z 86.1, C5H12N+ at m/z 104.1, C2H6O4P+
at m/z 125.0, C5H13NO3P+ at m/z 166.1, C5H15NO4P+ at m/z 184.1 and C8H19NO4P+ at m/z
224.1.33 The co-localization of amiodarone and lipid was expected. Amiodarone is extremely
lipophilic (log Poil/water = 6.3).34 The high propensity of amiodarone to accumulate in lipid-rich
regions contributes to its therapeutic properties as well as its adverse side effects. In a cardiac cell,
the incorporation of amiodarone into the cell membrane perturbs the properties of the phospholipid
bilayer structure and contributes to its antiarrhythmic abilities.35
Table 1: For the individual cells defined in the ion image in Figure 1C, the percent area of cover-
age, average amiodarone counts per pixel summed across the depth scale and cell diameters were
calculated. The average amiodarone count per pixel was calculated by dividing the background-
subtracted intensity of the peak at m/z 646.0 summed over the ROI by the total number of pixels
in the selected ROI.
ROI 1 ROI 2 ROI 3 ROI 4
Area (%) 9.82 3.25 5.79 2.55
Counts per pixel 8.5 2.7 3.3 2.4
Diameter (µm) 45 26 33 22
Variations in the morphology of the cell and relative cellular amiodarone ion signal intensity
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was observed throughout the population. Immortalized cell lines are typically considered to have
relatively homogeneous properties; however, cell-to-cell variations are expected. The SIMS image
was divided into four ROI and the chemical signature was examined for each cell (see Figure 1 D).
The approximate size and counts per pixel for the signal intensity of amiodarone for each cell is
reported in Table 1. The cells in ROI 3 and 4 are physically attached so the boundary was approx-
imated. The cell in ROI 1 is significantly larger and has relatively more intense amiodarone signal
(m/z 646.0) than the other cells in the ion image. The cell is potentially "foamy" and accumulating
lipid and drug. The cell in ROI 3 is most likely in the process of division, nuclear material is
localized in two regions of the cell and the cell is slightly larger than the cells defined in ROI 2 and
4.
With 3D ToF-SIMS imaging, the distribution of the drug and endogenous species are collected
as a function of depth. After the surface of the cells was sputtered away, the drug compound
(green) can be seen inside the cell (see Figure 2). Ion image at selected sputter cycles throughout
are displayed in Figure 3. For clarity, the ion image acquired before the first sputter cycle was not
included. The molecular ion peak of amiodarone was detected throughout the cell with the major-
ity of the compound signal observed in the surface and subsurface regions. Although the molecular
ion signal intensity diminished with depth, the signal of the molecular ion is still observed at a S/N
level above 3 throughout the analysis (see Figure 3 D and Table 2). It should be noted that the high
surface amiodarone signal intensity is most likely a result of the sample preparation method used
in this study and does not reflect an equilibrium state in culture. For more accurate intracellular
distributions, cryogenic sample preparation methods are required. Here, for the purposes of show-
ing the efficacy of detecting drug uptake at the single cell level and therapeutic doses, the cells
were freeze-dried.
The presence of the drug compound deep inside the cell, as shown in Figure 3, is clear evidence
of cellular uptake. This observation is supported by conventional radio-labeling studies preformed
by Stadler and co-workers.30 Through the systematic inhibition of the endocytotic pathways (i.e.
clathrin-mediated, caveolae-mediated, phagocytosis) studies show that amiodarone does not have
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Table 2: The signal-to-noise (S/N) and maximum count (MC) for the molecular ion of the drug
compound for various sputter cycles throughout the cell in Figure 1 defined by ROI 1 are provided.
Dose (ions/cm2) cycle number S/N MC
7.4-18.5 x 1013 2-5 81.7 1550
1.85-3.7 x 1014 5-10 67.88 1100
3.7-5.6 x 1014 10-15 33.71 480
5.6-7.4 x 1014 15-20 22.85 221
7.4-9.3 x 1014 20-25 15.8 124
0.9-1.1 x 1015 25-30 11.2 92
1.1-1.3 x 1015 30-35 8.9 50
1.3-1.5 x 1015 35-40 7.6 36
a preferred endocytotic pathway, it is internalized through various methods and routes.30 Unfortu-
nately, since the quantity of the radiation released by radio-isotope is independent of the structure
of the tracer molecule, it is impossible to differentiate the drug molecule from its metabolites.
Therefore, the use of radioactive isotopic labels is further complicated by the tracer’s potential to
change the metabolic pathway and cellular damages from the emission of radio-active beta parti-
cles.36 The direct in situ detection of the drug and its metabolites with SIMS, eliminates the need
for isotopic labels.
We evaluated the efficacy of SIMS in the detection of desethylamiodarone, the main metabo-
lite of amiodarone. Amiodarone is metabolized by the cytochrome P450 (CYP450) enzymes,
specifically cytochrome P450 isoform CYP3A437 and CYP2C838 in the liver. Since the cell line
does not metabolize amiodarone, the lung macrophages were doped with desethylamiodarone.37,39
The metabolite has also been shown to accumulate in lung macrophages and contribute to the
toxic effect of the drug.40 The SIMS image shows the protonated molecule of the metabolite,
[(C23H25I2NO3)+H]+, which was detected at m/z 618.0 (see Figure 4). The cellular localization
exhibited by the metabolite was similar to its precursor; it was co-localized with the lipid through
the cell and absent in the nucleus. In Figure 4A, the cluster of cells in the center of the ion image
have a higher count per pixel intensity of the metabolite peak, suggesting accumulation.
High lateral resolution ion image of a cell doped with the amiodarone metabolite, desethy-
lamiodarone, are shown in Figure 5A. In the ion image, the iodine signal, I−, at m/z 127 (green)
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was found throughout the cell, but was absent in the nuclear regions (red). The distribution was
consistent with the high mass resolution experiments for both amiodarone and desthlamiodarone.
In the negative ion mode, adenine (C5H4N5−) at m/z 134.1 and two phosphate-oxygen fragments,
HP2O−6 at m/z 158.9 and NaP2O
−
6 at m/z 180.9, were used as nuclear markers. The nuclear mor-
phology, elucidated in the 3D isosurface rendering in Figure 5B, provides a clear intercellular
interface to measure the image resolution. A linescan across the nucleus-drug interface was fitted
with a erf (black) and the FWHM lateral resolution was measured to be 550 nm. In the high lateral
resolution imaging mode, the limited ion beam current and long pulse duration reduced the quality
of the mass spectral data. As a result, only the iodine in the analyte molecule was present at a
sufficient intensity to map its distribution. In present ToF-SIMS instruments, the loss of chemical
specificity associated with high lateral resolution imaging experiments prevents its use in animal
studies. Since both the drug and metabolite has an iodine group, the two compounds would not
be distinguishable when analyzing excised tissue from an animal model. In the NR8383 model
system, as previously mentioned, the cell line is unable to metabolize the compound, therefore, we
are confident that the iodine signal is from the dosed analyte.
Amiodarone has several advantageous properties that make it ideal for mass spectrometry ana-
lyzes, particularly ToF-SIMS. The drug compound has two iodine functional groups. Iodine has the
largest mass defect of all the elements; the exact mass of the mono-isotope is 126.9044,41 which
is approximately -753 ppm deviation from the nominal mass. These functional group shift the
drug peak to a lower mass-to-charge than the isobaric hydrocarbon-containing species, reducing
the potential for spectral interference with endogenous biomolecules. It is also fortunate that this
particular drug compound falls within a relatively quiet region of the mass spectrum; clear from
the phospholipid region and from sterols and diacylgylcerides species.33 Also, the tertiary amine
in the di-ethylamine moiety, which is reduced to a secondary amine group when metabolized, most
likely stabilizes the positively charged species in the gas phase, improving its secondary ion yields
compared to the metabolite.
In this case, the chemical features of amiodarone, as described in the supporting information,
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facilitated the detection and identification of the compound inside the cells. However, this is often
not the case. A significant proportion of pharmaceuticals are small organic molecules that fall
within congested regions of the mass spectrum and experience isotopic interference. The MALDI
community has employed the high mass resolution of FT-based detection schemes to overcome
isobaric interference to image drugs in tissues.42,43 Efforts are currently underway to incorporate
this technology into SIMS instrumentation.44 New instrumental developments will help to expand
the use of SIMS in pharmaceutical applications.
Overall, we have shown that 3D-ToF SIMS provides important pharmacokinetic information on
the distribution of drugs and metabolites in single cells. Chemical cues from endogenous species
were used to identify and correlate the location of large organelles with the distribution of the drug
compound. On the single cell level, variations in the cell size, cell cycle stage and the relative
amount of drug compound were observed. 3D imaging of pharmaceutical distributions on the sin-
gle cell level is an exciting new application for SIMS and the amiodarone-macrophages system is
a potential model for future pharmaceutical applications.
Acknowledgement
The authors thank Dr. Dave Hassall and Dr. Andy Nichols of GlaxoSmithKline for discussions
on the experimental design of the amiodarone and NR8383 study. We also thank Dr. Alex Shard
for his discussion and comments on this manuscript. This work was funded by the 3D nanoSIMS
project in the strategic capabilities program of the National Measurement System of the UK De-
partment of Business, Innovation and Skills and by the National Centre for replacement, Refine-
ment and Reduction of Animals in Research (NC3Rs) NC/C013110/1.
Contributions: Performed biological research: CFN; Performed SIMS research: MKP, CFN;
Analyzed data and wrote the paper: MKP; initial design: JB, PSM; Academic advisor to CFN:
MA; Direction: CTD, AW, ISG; Funding: JB, ISG.
11
Notes and References
(1) Plomp, T.; Van Rossum, J.; Robles, d. M. E.; Van Lier, T.; Maes, R. Drug. Res. 1983, 34,
513–520.
(2) Dollery, C. Clin. Pharmacol. Ther. 2012, 93, 263–266.
(3) Greer, T.; Sturm, R.; Li, L. J. Proteomics 2011, 74, 2617–2631.
(4) Rubakhin, S. S.; Jurchen, J. C.; Monroe, E. B.; Sweedler, J. V. Drug Discov. Today 2005,
10, 823–837.
(5) Prideaux, B.; Stoeckli, M. J. Proteomics 2012, 75, 4999–5013.
(6) Nilsson, A.; Goodwin, R. J.; Shariatgorji, M.; Vallianatou, T.; Webborn, P. J.; Andrén, P. E.
Anal. Chem. 2014, .
(7) Spengler, B.; Hubert, M. J. Am. Soc. Mass Spectrom. 2002, 13, 735–748.
(8) Schober, Y.; Guenther, S.; Spengler, B.; RoÌL´mpp, A. Anal. chem. 2012, 84, 6293–6297.
(9) Zavalin, A.; Todd, E. M.; Rawhouser, P. D.; Yang, J.; Norris, J. L.; Caprioli, R. M. J. Mass
Spectrom. 2012, 47, 1473–1481.
(10) Fisher, G. L.; Belu, A. M.; Mahoney, C. M.; Wormuth, K.; Sanada, N. Anal. Chem. 2009,
81, 9930–9940.
(11) Belu, A.; Mahoney, C.; Wormuth, K. J. Control. Release 2008, 126, 111–121.
(12) John, C.; Odom, R.; Salvati, L.; Annapragada, A.; Lu, M. F. Anal. Chem 1995, 67, 3871–
3878.
(13) Trouillon, R.; Passarelli, M. K.; Wang, J.; Kurczy, M. E.; Ewing, A. G. Anal. Chem 2012,
85, 522–542.
(14) Passarelli, M. K.; Ewing, A. G. Curr. Opin. Chem. Biol. 2013, 17, 854–859.
12
(15) Gilmore, I. S. JVST A 2013, 31, 050819.
(16) Passarelli, M. K.; Ewing, A. G.; Winograd, N. Anal. Chem 2013, 85, 2231–2238.
(17) Fletcher, J. S.; Rabbani, S.; Henderson, A.; Blenkinsopp, P.; Thompson, S. P.; Lock-
yer, N. P.; Vickerman, J. C. Anal. chem. 2008, 80, 9058–9064.
(18) Winograd, N. Anal. Chem. 2005, 77, 142–A.
(19) Winograd, N. Anal. Chem. 2014, 87, 328–333.
(20) Nygren, H.; Eriksson, C.; Malmberg, P.; Sahlin, H.; Carlsson, L.; Lausmaa, J.; Sjövall, P.
Colloids Surf., B 2003, 30, 87–92.
(21) Seah, M. Surf. Interface Anal. 2002, 33, 950–953.
(22) Passarelli, M. K.; Wang, J.; Mohammadi, A. S.; Trouillon, R.; Gilmore, I.; Ewing, A. G.
Anal. chem. 2014, 86, 9473–9480.
(23) Papiris, S. A.; Triantafillidou, C.; Kolilekas, L.; Markoulaki, D.; Manali, E. D. Drug Saf. .
(24) Dusman, R. E.; Stanton, M. S.; Miles, W. M.; Klein, L. S.; Zipes, D. P.; Fineberg, N. S.;
Heger, J. J. Circulation 1990, 82, 51–59.
(25) Rotmensch, H. H.; Belhassen, B.; Swanson, B. N.; Shoshani, D.; Spielman, S. R.; Green-
spon, A. J.; Grenspan, A. M.; Vlasses, P. H.; Horowitz, L. N. Ann. Intern. Med. 1984, 101,
462–469.
(26) Anderson, N.; Borlak, J. FEBS Lett. 2006, 580, 5533–5540.
(27) Mesens, N.; Desmidt, M.; Verheyen, G. R.; Starckx, S.; Damsch, S.; De Vries, R.; Ver-
hemeldonck, M.; Van Gompel, J.; Lampo, A.; Lammens, L. Toxicol. Pathol. 2012, 40,
491–503.
(28) Reasor, M. J.; Ogle, C. L.; Miles, P. R. Exp Lung Res 1990, 16, 577–591.
13
(29) Abe, A.; Shayman, J. A. J. Lipid Res. 2009, 50, 2027–2035.
(30) Stadler, K.; Ha, H. R.; Ciminale, V.; Spirli, C.; Saletti, G.; Schiavon, M.; Bruttomesso, D.;
Bigler, L.; Follath, F.; Pettenazzo, A.; Baritussio, A. Am. J. Respir. Cell Mol. Biol. 2008,
39, 142–149.
(31) Rao, A. N.; Vandencasteele, N.; Gamble, L. J.; Grainger, D. W. Anal. chem. 2012, 84,
10628.
(32) Tyler, B. J. TOF-SIMS: Materials Analysis by Mass Spectrometry 2013, 485.
(33) Passarelli, M. K.; Winograd, N. BBA- Mol.Cell Biol. L. 2011, 1811, 976–990.
(34) Trumbore, M.; Chester, D.; Moring, J.; Rhodes, D.; Herbette, L. Biophys. J. 1988, 54,
535–543.
(35) Maresova, L.; Muend, S.; Zhang, Y.-Q.; Sychrova, H.; Rao, R. J. Biol Chem. 2009, 284,
2795–2802.
(36) Hu, V. W.; Heikka, D. S.; Dieffenbach, P. B.; Ha, L. FASEB J. 2001, 15, 1562–1568.
(37) Zahno, A.; Brecht, K.; Morand, R.; Maseneni, S.; Török, M.; Lindinger, P. W.; Krähen-
bühl, S. Biochem. Pharmacol. 2011, 81, 432–441.
(38) Ohyama, K.; Nakajima, M.; Nakamura, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. Drug
Metab. Dispos. 2000, 28, 1303–1310.
(39) Ohyama, K.; Nakajima, M.; Suzuki, M.; Shimada, N.; Yamazaki, H.; Yokoi, T. Br. J. Clin.
Pharmacol. 2000, 49, 244–253.
(40) Antonini, J. M.; Reasor, M. J. Biochem. Pharmacol. 1991, 42, S151–S156.
(41) Lide, D. R. “Handbook of chemistry and physics 95th edition”, 2014.
(42) Cornett, D. S.; Frappier, S. L.; Caprioli, R. M. Anal. Chem. 2008, 80, 5648–5653.
14
(43) Marko-Varga, G.; Fehniger, T. E.; Rezeli, M.; Döme, B.; Laurell, T.; Végvári, Á. J.
Proteomics 2011, 74, 982–992.
(44) http://www.npl.co.uk/news/3d-nanosims-label-free-molecular-imaging.
15
Graphical TOC Entry
16
Figure 1: A) Regions of the mass spectrum obtained from a single cell showing the drug-related
peaks, including the protonated molecule at m/z 646.0 and fragment ion at m/z 520.1. The molec-
ular structure of the pharmaceutical compound amiodarone is also shown. B) The ion image of
amiodarone summed over the entire depth range shows the distribution of drug compound within
individual cells. C) Overlaid ion image reveals the distribution of ribose (red), lipid (blue), and
drug (green) in cultured cells. D) Four regions of interest were defined on the total ion image and
the diameters of the individual cells were measured. E) Linescan of the ion intensities of phos-
phocholine fragment (m/z 184), ribose fragment (m/z 81) and amiodarone (m/z 646) across the
large cell in ROI 1 (linewidth = 3 image pixels, ion intensity summed across the depth scale). The
linescan shows a reduced drug and lipid signal in the region with high ribose signal intensities.
The intracellular interface between the ribose and drug signal was fitted with a error function (erf).
The lateral resolution was measured to 3.4 µm. [all scale bars = 20 µm]
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Figure 2: A) 3D rendering of macrophages dosed with amiodarone. The internal distribution of
amiodarone (m/z 646.0, green) is visible after the surface of the cells was sputtered away (1.85 x
1014 Ar2000/cm2, slice 5-40). The blue and red pixels represent the distribution of the lipid markers
at m/z 184.1 and the nuclear-markers at m/z 81.0, respectively. Note: The image is not corrected
for topography.
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Figure 3: A) The total ion SIMS images of the amiodarone-doped macrophages at various sputter
depths (maximum count 3000). B) Endogenous chemical signals for lipid markers (blue) at m/z
184.1 and nuclear-markers (red) at m/z 81.0 provide sub-cellular markers for the relative distribu-
tion of the drug, amiodarone (green). C) The protonated amiodarone molecular ion image shows
the cellular distribution of the drug compound D) Mass spectra showing the relative signal-to-noise
of the amiodarone peak at m/z 646.0 as a function of depth.
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Figure 4: A) The optical and RGB ion image showing the relative distribution of lipids (blue),
nuclear-markers (red) and amiodarone metabolite, desethylamiodarone (green) in macrophages.
B) The total ion contribution of the protonated molecule peak for desthylamiodarone at m/z 618.0.
C) The molecular structure of the drug-metabolite, desethylamiodarone. The drug molecule loses
a ethyl group from the nitrogen atom when it is metabolized in the liver. D) The RGB ion image of
control cells with lipid-markers (blue) and nuclear-markers (red). E) Mass spectra from cell doped
with amiodarone (green) and metabolite (blue), as well as, control cells (red). [All scale bars = 20
µm]
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Figure 5: A) High lateral resolution ion images of NR8383 macrophage doped with desethylamio-
darone in the negative ion mode at 7.8 x 1013 ions/cm2, 1.56 x 1014 ions/cm2, 2.34 x 1014 ions/cm2,
and 3.12 x 1014 ions/cm2 [row 1 = total ion images, row 2 = I− at m/z 127 (green) and the summed
ion contribution of the nuclear-markers at m/z 134, 158.9 and 180.9 (red)] B) 3D isosurface ren-
dering of the doped cell. Iodine, I−, at m/z 127 is mapped in green (opacity = 0.65) and nuclear
marker, HP2O−6 , at m/z 158.9 is mapped in red. [isosurface parameters: iso value = 16, median
kernel size = 4, images were smoothed with a gauss followed by a median filter.] C) Linescan
(line width = 3 image pixels) across the high lateral resolution ion image obtained after an argon
sputter dose of 1.95 x 1014 ion/cm2 (green = I− signal at m/z 127 and red = summed signal from
nuclear markers at m/z 134, 158.9 and 180.9) shows a reduced drug signal in the region with in-
tense nucleus-related signals. The intracellular interface between the nucleus and drug signal was
fitted with a error function (erf, black) and the lateral resolution was measured to 550 nm.
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